Paper Details

  1. Home
  2. Paper Details

Matching-adjusted indirect comparison of benralizumab <i>versus</i> interleukin-5 inhibitors for the treatment of severe asthma: a systematic review.

Author: BourdinArnaud, GolamSarowar, HusereauDon, LindnerLeandro, MolinariNicolas, SiddiquiMohd Kashif, XuXiao

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study used matching-adjusted indirect comparison (MAIC) to assess the relative efficacy of benralizumab versus mepolizumab and reslizumab in patients with severe, uncontrolled asthma. After matching adjustment, benralizumab and mepolizumab showed similar efficacy in reducing exacerbations and improving lung function.
Paper Details　
Original Abstract of the Article :
Benralizumab is an interleukin-5 receptor &#945;-directed cytolytic monoclonal antibody that directly depletes eosinophils. Its relative efficacy <i>versus</i> other IL-5-targeted treatments for patients with severe, uncontrolled asthma is not yet fully characterised.We performed a matching-adjusted...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277255/

データ提供：米国国立医学図書館（NLM）

Benralizumab vs. IL-5 Inhibitors for Severe Asthma: A Comparative Analysis

Asthma, a chronic respiratory condition, can severely impact the lives of millions of people around the world. Severe, uncontrolled asthma poses significant challenges for both patients and healthcare providers. This study enters the intricate world of asthma research, comparing the effectiveness of benralizumab, a targeted antibody therapy, to other interleukin-5 (IL-5) inhibitors in managing severe asthma. The researchers employed a matching-adjusted indirect comparison (MAIC) technique, a sophisticated method for comparing different treatments, to analyze the available data.

Benralizumab: A Promising Option for Severe Asthma

The study found that benralizumab and mepolizumab, both IL-5 inhibitors, showed similar effectiveness in reducing asthma exacerbations compared to placebo. This suggests that benralizumab offers a comparable level of benefit to other established IL-5 inhibitors, potentially providing a new option for patients with severe asthma who may not respond well to other treatments.

Breathing Easier: A Desert Oasis

For those living with severe asthma, the journey can be challenging, filled with frequent exacerbations and breathlessness. This study offers a glimmer of hope, suggesting that benralizumab might provide a new path to better breathing, improving the quality of life for patients with severe asthma.

Dr.Camel's Conclusion

This research highlights the potential of benralizumab as a valuable treatment option for severe asthma. The study's findings suggest that benralizumab provides comparable benefits to other IL-5 inhibitors, offering a new pathway to better breathing for patients struggling with this chronic condition.
Date :
  1. Date Completed 2019-09-10
  2. Date Revised 2019-09-10
Further Info :

Pubmed ID

30309978

DOI: Digital Object Identifier

PMC6277255

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.